This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CRNX

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

Crinetics Pharmaceuticals logo

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Key Stats

Today's Range
$84.95
▼
$84.95
50-Day Range
$83.52
▼
$84.95
52-Week Range
$30.25
▼
$85.01
Volume
N/A
Average Volume
2.43 million shs
Market Capitalization
$9.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$83.44
Consensus Rating
Hold

Company Overview

Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing orally delivered, small-molecule therapies for endocrine conditions and other hormone-related diseases. The company’s research is centered on medicines designed to act on peptide hormone receptors, with the goal of providing alternatives to injectable therapies.

Crinetics’ lead product candidate is paltusotine, an oral, selective somatostatin receptor type 2 agonist being developed for the treatment of acromegaly, a rare disorder caused by excessive growth hormone production. The company is also developing atumelnant, formerly known as CRN04894, an oral adrenocorticotropic hormone receptor antagonist being investigated for conditions including congenital adrenal hyperplasia and Cushing’s disease.

Founded in 2008 and headquartered in San Diego, California, Crinetics conducts research and clinical development activities intended to serve patients in the United States and international markets. The company’s leadership includes founder and Chief Executive Officer Scott Struthers, Ph.D., who has guided the organization’s focus on orally administered therapies for endocrine disorders.

AI Generated. May Contain Errors.

Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRNX Stock News Headlines

Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
See More Headlines

CRNX Stock Analysis - Frequently Asked Questions

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its quarterly earnings data on Monday, August, 3rd. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.18) by $0.04. The company's revenue for the quarter was up 2336.9% compared to the same quarter last year.

Crinetics Pharmaceuticals (CRNX) raised $96 million in an initial public offering on Wednesday, July 18th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Top institutional investors of Crinetics Pharmaceuticals include Allworth Financial LP and Allworth Financial LP. Insiders that own company stock include Richard Scott Struthers, Stephen F Betz, Marc Wilson, Jeff E Knight, Tobin Schilke, Dana Pizzuti, James Hassard, Matthew K Fust, Coelho Rogerio Vivaldi, Stephanie Okey and Isabel Kalofonos.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Plug Power (PLUG), Tesla (TSLA), NIO (NIO), Block (XYZ) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
8/03/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CRNX
CIK
1658247
Fax
N/A
Employees
210
Year Founded
2008

Price Target and Rating

High Price Target
$95.00
Low Price Target
$67.00
Potential Upside/Downside
-1.8%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$465.32 million
Net Margins
-1,189.88%
Pretax Margin
-1,189.45%
Return on Equity
-44.22%
Return on Assets
-39.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.57
Quick Ratio
15.53

Sales & Book Value

Annual Sales
$7.70 million
Price / Sales
1,170.54
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.23 per share
Price / Book
7.56

Miscellaneous

Outstanding Shares
106,100,000
Free Float
102,063,000
Market Cap
$9.01 billion
Optionable
Optionable
Beta
0.08

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:CRNX) was last updated on 9/1/2026 by MarketBeat.com Staff.
From Our Partners